Wu Ying, Lu Man, Zhou Qiaodan
Department of Ultrasound, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu 610072, China.
J BUON. 2015 May-Jun;20(3):855-61.
Kallikrein is considered as a mediator of tumorigenesis. Various studies examing the relationship between high kallikrein expressions with the clinical outcome in patients with ovarian cancer have yielded controversial conclusions.
We conducted a meta-analysis of 10 studies (N=1478) that evaluated the relationship between positive kallikrein expression and overall survival and progression-free survival (PFS). Data were analyzed with random effect and combined hazard ratios (HR) by STATA software.
Positive kallikrein expression was significantly associated with worse OS (HR for OS was 2.01, 95%CI: 1.68-2.34, p<0.05). Subgroup analysis showed that kallikrein detected by RT-PCR was related with OS (HR=2.51, 95%CI: 2.16-2.86, p<0.05), as well as by nonY-PCR methods (HR=1.6, 95%CI: 1.08-2.12, p<0.05). The heterogeneity among studies was significant (I2-91%, p=0.000). Begg's and Egger's test showed p=0.813 and p=0.938, respectively. The estimated HR for PFS was 1.83, 95%CI: 1.51-2.14, p<0.05). The heterogeneity among studies was significant (I2=88.9%, p=0.000). Begg's and Egger's test showed p=0.93 and p=0.88, respectively. Furthermore, confunnel plot (contour-enhanced funnel plot) was undertaken which also showed absence of publication bias for both OS and PFS.
Although the presence of some modest bias cannot be avoided, positive kallikrein expression seems to be associated with worse OS and PFS in patients with ovarian cancer.
激肽释放酶被认为是肿瘤发生的介质。各种研究探讨了卵巢癌患者中激肽释放酶高表达与临床结局之间的关系，但得出了相互矛盾的结论。
我们对10项研究（N = 1478）进行了荟萃分析，这些研究评估了激肽释放酶阳性表达与总生存期和无进展生存期（PFS）之间的关系。数据采用随机效应分析，并通过STATA软件合并风险比（HR）。
激肽释放酶阳性表达与较差的总生存期显著相关（总生存期的HR为2.01，95%CI：1.68 - 2.34，p < 0.05）。亚组分析表明，通过逆转录聚合酶链反应（RT-PCR）检测的激肽释放酶与总生存期相关（HR = 2.51，95%CI：2.16 - 2.86，p < 0.05），通过非RT-PCR方法检测的激肽释放酶也与总生存期相关（HR = 1.6，95%CI：1.08 - 2.12，p < 0.05）。研究之间的异质性显著（I² = 91%，p = 0.000）。Begg检验和Egger检验分别显示p = 0.813和p = 0.938。无进展生存期的估计HR为1.83，95%CI：1.51 - 2.14，p < 0.05）。研究之间的异质性显著（I² = 88.9%，p = 0.000）。Begg检验和Egger检验分别显示p = 0.93和p = 0.88。此外，进行了漏斗图（等高线增强漏斗图）分析，结果也显示总生存期和无进展生存期均不存在发表偏倚。
尽管无法避免一些适度偏倚的存在，但激肽释放酶阳性表达似乎与卵巢癌患者较差的总生存期和无进展生存期相关。
